Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$34.32

0.76 (2.26%)

19:52
07/25/18
07/25
19:52
07/25/18
19:52

Boston Scientific price target raised to $38 from $32.50 at Piper Jaffray

Piper Jaffray analyst Matt O'Brien raised his price target on Boston Scientific to $38 after its better than expected Q2 results. The analyst notes that the quarter was "balanced across business segments and geographies with Rhythm Management", adding that the management also narrowed higher its FY18 organic growth rate targets. O'Brien also cites another quarter of strength in the emerging markets, keeping his Overweight rating on expectations of "expanded product indications, clinical data in Q3, and the successful integration of several new acquisitions".

  • 25

    Jul

  • 14

    Aug

  • 15

    Aug

BSX Boston Scientific
$34.32

0.76 (2.26%)

07/25/18
JPMS
07/25/18
NO CHANGE
Target $77
JPMS
Overweight
Nevro selloff yesterday a 'clear buying opportunity,' says JPMorgan
JPMorgan analyst Robbie Marcus views yesterday's selloff in shares of Nevro (NVRO) as a "clear buying opportunity." The headlines suggest Boston Scientific (BSX) was the clear winner in the summary judgment, but the "nuance in the actual ruling swings this in favor of Nevro," Marcus tells investors in a research note. The analyst's interpretation is that while Boston doesn't infringe Nevro's three remaining patents with its current trials and U.S. commercialized tonic stimulation devices, the ruling implies that any attempt to actually commercialize a high-frequency device in the U.S. remains an infringement of Nevro's remaining patents '102 and '472. While Nevro's systems claims patents were ruled invalid, the company's broader method claim patents were upheld, Marcus writes. He keeps an Overweight rating on Nevro with a $77 price target. The stock closed yesterday down 26%, or $15.78, to $44.22.
07/25/18
ADAM
07/25/18
NO CHANGE
Target $80
ADAM
Buy
Nevro weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the weakness in Nevro (NVRO) following a summary judgment announced yesterday in its patent dispute with Boston Scientific (BSX) is a buying opportunity. The analyst said the move yesterday priced in a worst-case scenario, implying Nevro will lose all IP protection over its HF-10kHz technology, but he believes the current situation is more nuanced and the ultimate outcomes remain fluid. He believes the market overreacted and he recommends investors buy the weakness. Mills reiterated his Buy rating and $80 price target on Nevro shares.
07/25/18
LEER
07/25/18
NO CHANGE
Target $90
LEER
Outperform
Nevro selloff overdone, says Leerink
Leerink analyst Danielle Antalffy is defending Nevro (NVRO) shares after a 26% selloff in response to a summary judgment ruling in which either the company's patents were ruled invalid or Boston Scientific (BSX) was ruled to not infringe. The analyst believes that even in a worst-case scenario, namely one in which Nevro's patents are invalidated, allowing other manufacturers to pursue high frequency therapy, the company would still be able to grow sales by about 5% in 2019. Antalffy reiterates an Outperform rating and $90 price target on Nevro's shares as she continues to believe the company's fundamentals remain relatively strong, particularly given where the stock is currently trading.
07/25/18
WBLR
07/25/18
NO CHANGE
WBLR
Outperform
Nevro patent ruling not as bad as it seems, says William Blair
William Blair analyst Margaret Kaczor says the summary judgement issued yesterday is not as bad as it seems for Nevro (NVRO). While the initial headline appears negative, the ruling is similar to the preliminary judgment published earlier this month, Kaczor tells investors in a research note. Though some of the claims in the patents have been invalidated, the remaining claims, which include frequency ranges of 1.5 kHz to 100 kHz, were not invalidated, the analyst adds. She points out, though, that the judge found Boston Scientific (BSX) did not infringe on the claims as its commercially available devices could not be programmed to frequencies that would infringe and that devices that could be programmed to high frequency that are being used in clinical trials are included in safe harbor provisions. This leaves the door open in the event that Boston commercially launches a device within the frequency ranges referenced above, Kaczor writes. She believes, however, that even if Boston moves to launch a high frequency device in the United States, the company would likely have to file for FDA approval following the completion of its high-frequency trial. Despite some level of uncertainty this ruling may bring, Nevro's risk/reward is favorable, Kaczor contends. She keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/19/19
07/19
16:20
07/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCBP

BCB Bancorp

$12.71

-0.09 (-0.70%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Earnings
BCB Bancorp reports Q2 EPS 30c, consensus 30c »

Net interest margin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNXM

CNX Midstream Partners

$14.30

-0.205 (-1.41%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Hot Stocks
CNX Midstream Partners raises quarterly distribution 3.6% to 38.65c per unit »

CNX Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$7.25

0.22 (3.13%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Syndicate
Breaking Syndicate news story on Tellurian »

Tellurian files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
07/19/19
07/19
16:15
07/19/19
16:15
General news
Breaking General news story  »

Boston Federal Reserve…

ROKU

Roku

$106.83

-2.18 (-2.00%)

16:13
07/19/19
07/19
16:13
07/19/19
16:13
Conference/Events
Roku management to meet with Oppenheimer »

Bull/Bear Luncheon to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 07

    Aug

EHTH

eHealth

$86.91

-0.59 (-0.67%)

16:12
07/19/19
07/19
16:12
07/19/19
16:12
Initiation
eHealth initiated  »

eHealth initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 14

    Aug

JEF

Jefferies Financial Group

$20.95

-0.13 (-0.62%)

16:11
07/19/19
07/19
16:11
07/19/19
16:11
Conference/Events
Jefferies Financial Group management to meet with Oppenheimer »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

XXII

22nd Century

$1.94

0.04 (2.11%)

16:10
07/19/19
07/19
16:10
07/19/19
16:10
Hot Stocks
22nd Century: FDA accepts, files MRTP application for VLN cigarettes »

22nd Century announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOI

Solaris Oilfield

$13.12

(0.00%)

16:10
07/19/19
07/19
16:10
07/19/19
16:10
Earnings
Solaris Oilfield reports preliminary Q2 revenue $63M-$65M, consensus $58.04M »

"Our second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Aug

CCNE

CNB Financial

$26.76

0.12 (0.45%)

16:05
07/19/19
07/19
16:05
07/19/19
16:05
Earnings
CNB Financial reports Q2 EPS 64c, two estimates 58c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.81

-0.0999 (-10.98%)

16:05
07/19/19
07/19
16:05
07/19/19
16:05
Hot Stocks
Caxton Corp reports 5.3% passive stake in Sunesis »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRI

Herc Holdings

$40.28

-0.62 (-1.52%)

16:04
07/19/19
07/19
16:04
07/19/19
16:04
Hot Stocks
Gabelli reports 18.15% stake in Herc Holdings »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GMAB

Genmab

$18.08

-0.12 (-0.66%)

15:55
07/19/19
07/19
15:55
07/19/19
15:55
Hot Stocks
Genmab discloses BlackRock stake in company reached 5% »

Genmab A/S announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

DISH

Dish

$40.69

-0.13 (-0.32%)

15:45
07/19/19
07/19
15:45
07/19/19
15:45
Options
Dish call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$19.04

0.5 (2.70%)

15:35
07/19/19
07/19
15:35
07/19/19
15:35
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

15:35
07/19/19
07/19
15:35
07/19/19
15:35
General news
Action Economics Survey results: »

Action Economics Survey…

15:35
07/19/19
07/19
15:35
07/19/19
15:35
General news
Treasury Market Outlook »

Treasury Market Outlook:…

JCP

J.C. Penney

$0.90

-0.175 (-16.28%)

15:32
07/19/19
07/19
15:32
07/19/19
15:32
Hot Stocks
J.C. Penney says has not hired advisors for in-court restructuring, bankruptcy »

J. C. Penney has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$154.32

-0.42 (-0.27%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:28
07/19/19
07/19
15:28
07/19/19
15:28
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

For the week, trading in…

IWM

iShares Trust Russell 2000 Index Fund

$154.32

-0.42 (-0.27%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.